锌指增强子同源物2作为癌症独立预后标志物的Meta分析
Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysis.
作者信息
Chen Shuling, Huang Lixia, Sun Kaiyu, Wu Dexi, Li Minrui, Li Manying, Zhong Bihui, Chen Minhu, Zhang Shenghong
机构信息
Division of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, P.R. China.
Division of Respiration, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, P.R. China.
出版信息
PLoS One. 2015 May 14;10(5):e0125480. doi: 10.1371/journal.pone.0125480. eCollection 2015.
BACKGROUND
Novel biomarkers are of particular interest for predicting cancer prognosis. This study aimed to explore the associations between enhancer of zeste homolog 2 (EZH2) and patient survival in various cancers.
METHODS
Relevant literature was retrieved from PubMed and Web of Science databases. Pooled hazard ratios (HRs), odds ratios (ORs), and 95% confidence intervals (CIs) were calculated.
RESULTS
Forty-nine studies (8,050 patients) were included. High EZH2 expression was significantly associated with shorter overall (hazard ratio [HR] 1.74, 95% CI: 1.46-2.07), disease-free (HR 1.59, 95% CI: 1.27-1.99), metastasis-free (HR 2.19, 95% CI: 1.38-3.47), progression-free (HR 2.53, 95% CI: 1.52-4.21), cancer-specific (HR 3.13, 95% CI: 1.70-5.74), and disease-specific (HR 2.29, 95% CI: 1.56-3.35) survival, but not recurrence-free survival (HR 1.38, 95% CI: 0.93-2.06). Moreover, EZH2 expression significantly correlated with distant metastasis (OR 3.25, 95% CI: 1.07-9.87) in esophageal carcinoma; differentiation (OR 3.00, 95% CI: 1.37-6.55) in non-small cell lung cancer; TNM stage (OR 3.18, 95% CI: 2.49-4.08) in renal cell carcinoma; and histological grade (OR 4.50, 95% CI: 3.33-6.09), estrogen receptor status (OR 0.15, 95% CI: 0.11-0.20) and progesterone receptor status (OR 0.30, 95% CI: 0.23-0.39) in breast cancer.
CONCLUSIONS
Our results suggested that EZH2 might be an independent prognostic factor for multiple survival measures in different cancers.
背景
新型生物标志物对于预测癌症预后尤为重要。本研究旨在探讨zeste同源物2增强子（EZH2）与各种癌症患者生存率之间的关联。
方法
从PubMed和Web of Science数据库中检索相关文献。计算合并风险比（HRs）、比值比（ORs）和95%置信区间（CIs）。
结果
纳入49项研究（共8050例患者）。EZH2高表达与总体生存期缩短（风险比[HR]1.74，95%CI：1.46 - 2.07）、无病生存期缩短（HR 1.59，95%CI：1.27 - 1.99）、无转移生存期缩短（HR 2.19，95%CI：1.38 - 3.47）、无进展生存期缩短（HR 2.53，95%CI：1.52 - 4.21）、癌症特异性生存期缩短（HR 3.13，95%CI：1.70 - 5.74）和疾病特异性生存期缩短（HR 2.29，95%CI：1.56 - 3.35）显著相关，但与无复发生存期无关（HR 1.38，95%CI：0.93 - 2.06）。此外，EZH2表达与食管癌远处转移（OR 3.25，95%CI：1.07 - 9.87）、非小细胞肺癌分化程度（OR 3.00，95%CI：1.37 - 6.55）、肾细胞癌TNM分期（OR 3.18，95%CI：2.49 - 4.08）以及乳腺癌组织学分级（OR 4.50，95%CI：3.33 - 6.09）、雌激素受体状态（OR 0.15，95%CI：0.11 - 0.20）和孕激素受体状态（OR 0.30，95%CI：0.23 - 0.39）显著相关。
结论
我们的结果表明，EZH2可能是不同癌症多种生存指标的独立预后因素。
Zotero 插件